NCT06159244 Intestinal Microbiota Profiling in Severe Acute Alcoholic Hepatitis Patients
| NCT ID | NCT06159244 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire, Amiens |
| Condition | Severe Acute Alcoholic Hepatitis |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2023-11-15 |
| Primary Completion | 2028-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2023-11-15 with a primary completion date of 2028-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In humans, alcohol-related dysbiosis exists with a decrease in bacteroides. This dysbiosis is responsible for the breakdown of the intestinal barrier by a decrease in the synthesis of protective mucus, and some proteins involved in tight junctions or a decrease in defensin (Reg3b, Reg3g) which promotes bacterial growth and ultimately bacterial translocation. The microbiota of a patient with alcoholic hepatitis is different from that of a patient without alcoholic hepatitis. Acute alcoholic hepatitis has a severe prognosis and corticosteroids are the only first line therapy option, with better survival at 28 days versus placebo. However, mortality remains high at 30% at 3 months, which highlights the importance of seeking intestinal microbiota profile on treatment response. The determination of one or more intestinal microbiota signatures associated with the treatment response Corticosteroids plus FMT or Corticosteroids plus placebo will allow the clinician to have a simple and rapid test obtained in 16S RNA analysis to predict the therapeutic response and potentially the best treatment to adopt and to address medical and medico-economic stakes. The investigators will first characterize the alcohol-induced dysbiosis by a whole microbiota sequencing in the different groups. Specific bacterial species identify by DNA sequencing should be confirmed by qPCR of 16S rDNA to determine a fingerprint of sAH microbiota. Metabolic properties of intestinal microbiota, such as production of short chain fatty acids, will be analyzed by using HPLC. In the sAH group, evolution of intestinal microbiota will be observed by shotgun DNA sequencing between the day 0 and the day 7 of corticosteroids treatment. The analysis of sAH patients' microbiota (day 0) will allow us to obtain a non-responder profile to corticosteroids that can be used as a prognostic marker to use in the clinic. The deliverable is the bacterial fingerprint of the treatment response and its valuation is its use as a predictive tool of the response.
Eligibility Criteria
Inclusion Criteria: * Patients aged from 18 to 75 years, having : * Heavy drinker with Maddrey Score ≥ 32 : PT(second)-PT(control)x4.6+Bilirubine (mg/dl) * Histological confirmed Alcoholic hepatitis * Personal consent signed to the trial * No exclusion criteria Exclusion Criteria: * Age \< 18 years and/or \> 75 years, * Pregnancy or lactating females, * No personal consent * Other causes of liver disease: chronic hepatitis B (antigen HBs positive), hepatitis C (HCV RNA positive), acetaminophen hepatotoxicity, biliary obstruction, autoimmune hepatitis, primary biliary cholangitis, primary sclerosis cholangitis, alpha 1 antitrypsine deficiency, and Wilson disease. * Uncontrolled liver complications: * Upper gastrointestinal bleed by portal hypertension (4 days required for stable condition) * Active sepsis (4 days required for stable condition) * Patient currently treated by antibiotic * Concomitant Liver cancer (HCC) or extrahepatic malignancy * Type 1 hepatorenal syndrome (HRS) or renal failure defined as a serum creatinine \>221 μmol/L (\>2.5 mg/dL) or the requirement for renal replacement therapy * Grade 4 Hepatic Encephalopathy (HE) by West Haven criteria * Individuals dependent on inotropic (eg, epinephrine or norepinephrine) or ventilatory support (ie, endotracheal intubation or positive-pressure ventilation) * Disseminated intravascular coagulation * Intestinal paralysis * History of liver transplantation Other general diseases or severe conditions: * HIV disease * Intestinal paralysis * Intestinal inflammatory disease (Crohn or Ulcerative colitis) * Clostridium difficilae infection * Clinical suspicion of pneumonia * Uncontrolled sepsis * Acute Alcoholic pancreatitis * Noncontrolled alcohol withdrawal syndrome * Cardiac or respiratory bad conditions
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06159244 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Severe Acute Alcoholic Hepatitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06159244 currently recruiting?
Yes, NCT06159244 is actively recruiting participants. Contact the research team at nguyen-khac.eric@chu-amiens.fr for enrollment information.
Where is the NCT06159244 trial being conducted?
This trial is being conducted at Amiens, France.
Who is sponsoring the NCT06159244 clinical trial?
NCT06159244 is sponsored by Centre Hospitalier Universitaire, Amiens. The trial plans to enroll 200 participants.